AROA BIOSURGERY LIMITED — Capital/Financing Update 2021

Aug 3, 2021

ASX ANNOUNCEMENT/MEDIA RELEASE 4 August 2021

==> picture [53 x 53] intentionally omitted <==

S ECTIO N 708A NO TICE

==> picture [45 x 10] intentionally omitted <==

This notice is given by Aroa Biosurgery Limited ( Company ) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

• (a) it has today issued 40,343,348 fully paid ordinary shares at an issue price of $1.165 per share to professional and sophisticated investors in relation to the Placement announced on 29 July 2021;

• (b) the shares referred to in paragraph (a) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

• (c) the Company is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act;

• (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:

• (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

• (ii) Section 674 of the Corporations Act as it applies to the Company; and

• (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Jim McLean, Independent Chair.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to ‘unlocking regenerative healing for everybody’, its products are developed from the Company’s proprietary Endoform® technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Clinically proven with peer reviewed publications, Aroa’s products have been used in more than four million procedures to date, with distribution into its key market of the United States by Appulse and Tela Bio. Founded in 2008, Aroa is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com/

Contacts

ontacts
Investor	Media
Simon Hinsley	Australia	New Zealand
Investor Relations	Matthew Wright	Piet De Jong
shinsley@aroabio.com	matt@nwrcommunications.com.au	piet.dejong@baldwinboyle.com
+ 61 401 809 653	+61 451 896 420	+64 21 812 766

==> picture [272 x 33] intentionally omitted <==

AROA BIOSURGERY LIMITED ARBN 638 867 473 NZCN 1980577 64 Richard Pearse Drive, Auckland 2022, New Zealand AROABIO.COM